SMT201900509T1 - Derivati di imidazopiridazina come inibitori di pi3kbeta - Google Patents

Derivati di imidazopiridazina come inibitori di pi3kbeta

Info

Publication number
SMT201900509T1
SMT201900509T1 SM20190509T SMT201900509T SMT201900509T1 SM T201900509 T1 SMT201900509 T1 SM T201900509T1 SM 20190509 T SM20190509 T SM 20190509T SM T201900509 T SMT201900509 T SM T201900509T SM T201900509 T1 SMT201900509 T1 SM T201900509T1
Authority
SM
San Marino
Prior art keywords
pi3kbeta
inhibitors
imidazopyridazine derivatives
imidazopyridazine
derivatives
Prior art date
Application number
SM20190509T
Other languages
English (en)
Italian (it)
Inventor
Lieven Meerpoel
Laurence Anne Mevellec
Sophie Coupa
Virginie Sophie Poncelet
Isabelle Noëlle Constance Pilatte
Elisabeth Thérèse Jeanne Pasquier
Didier Jean-Claude Berthelot
Olivier Alexis Georges Querolle
Christophe Meyer
Patrick René Angibaud
Christophe Gabriel Marcel Demestre
Guillaume Jean Maurice Mercey
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of SMT201900509T1 publication Critical patent/SMT201900509T1/it

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Taps Or Cocks (AREA)
SM20190509T 2014-12-19 2015-12-18 Derivati di imidazopiridazina come inibitori di pi3kbeta SMT201900509T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14199322 2014-12-19
PCT/EP2015/080604 WO2016097347A1 (en) 2014-12-19 2015-12-18 IMIDAZOPYRIDAZINE DERIVATIVES AS ΡΙ3Κβ INHIBITORS
EP15810784.7A EP3233862B1 (en) 2014-12-19 2015-12-18 Imidazopyridazine derivatives as pi3kbeta inhibitors

Publications (1)

Publication Number Publication Date
SMT201900509T1 true SMT201900509T1 (it) 2019-11-13

Family

ID=52134002

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20190509T SMT201900509T1 (it) 2014-12-19 2015-12-18 Derivati di imidazopiridazina come inibitori di pi3kbeta

Country Status (26)

Country Link
US (1) US10087187B2 (OSRAM)
EP (1) EP3233862B1 (OSRAM)
JP (1) JP6568588B2 (OSRAM)
KR (1) KR20170095239A (OSRAM)
CN (1) CN107108634B (OSRAM)
AU (1) AU2015366190B2 (OSRAM)
BR (1) BR112017012930A2 (OSRAM)
CA (1) CA2967551A1 (OSRAM)
CY (1) CY1122381T1 (OSRAM)
DK (1) DK3233862T3 (OSRAM)
EA (1) EA029789B1 (OSRAM)
ES (1) ES2761051T3 (OSRAM)
HR (1) HRP20191550T1 (OSRAM)
HU (1) HUE045220T2 (OSRAM)
IL (1) IL252866B (OSRAM)
LT (1) LT3233862T (OSRAM)
MA (1) MA41174B1 (OSRAM)
MD (1) MD3233862T2 (OSRAM)
ME (1) ME03517B (OSRAM)
MX (1) MX2017008074A (OSRAM)
PL (1) PL3233862T3 (OSRAM)
PT (1) PT3233862T (OSRAM)
RS (1) RS59301B1 (OSRAM)
SI (1) SI3233862T1 (OSRAM)
SM (1) SMT201900509T1 (OSRAM)
WO (1) WO2016097347A1 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018007068B1 (pt) 2015-10-09 2024-01-02 Janssen Pharmaceutica N.V. Derivados de quinoxalina e piridopirazina como inibidores de pi3kbeta, seu uso e composição farmacêutica que os compreende
WO2017216292A1 (en) 2016-06-16 2017-12-21 Janssen Pharmaceutica Nv Bicyclic pyridine, pyrazine, and pyrimidine derivatives as pi3k beta inhibitors
JP7053654B2 (ja) 2017-03-29 2022-04-12 ヤンセン ファーマシューティカ エヌ.ベー. PI3Kβ阻害剤としてのキノキサリン及びピリドピラジン誘導体
KR102853071B1 (ko) 2019-02-07 2025-09-02 베이진 엘티디 Tlr7 작용제로서의 이미다조[2,1-f][1,2,4]트리아진-4-아민 유도체
CN110128505A (zh) * 2019-05-21 2019-08-16 梯尔希(南京)药物研发有限公司 一种戈舍瑞林杂质的合成方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
JP2009544723A (ja) 2006-07-24 2009-12-17 スミスクライン・ビーチャム・コーポレイション Pi3キナーゼ阻害剤としてのチオゾリジンジオン誘導体
CA2663091A1 (en) 2006-09-07 2008-03-13 Biogen Idec Ma Inc. Modulators of interleukin-1 receptor-associated kinase
US20100305113A1 (en) * 2007-05-09 2010-12-02 Hans-Georg Capraro Substituted Imidazopyridazines as Lipid Kinase Inhibitors
US20110046127A1 (en) * 2007-11-08 2011-02-24 Paolo Pevarello Imidazopyridazines for Use as Protein Kinase Inhibitors
JP5576802B2 (ja) * 2008-02-28 2014-08-20 ノバルティス アーゲー C−Metチロシンキナーゼ介在疾患の治療用のイミダゾ[1,2−b]ピリダジン誘導体
WO2010007099A1 (en) 2008-07-15 2010-01-21 Cellzome Limited 2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors
US9085560B2 (en) 2009-08-17 2015-07-21 Intellikine, Inc. Heterocyclic compounds and uses thereof
DE102009049679A1 (de) * 2009-10-19 2011-04-21 Merck Patent Gmbh Pyrazolopyrimidinderivate
WO2011058109A1 (en) 2009-11-12 2011-05-19 Ucb Pharma S.A. Fused bicyclic pyrrole and imidazole derivatives as kinase inhibitors
UY33304A (es) 2010-04-02 2011-10-31 Amgen Inc Compuestos heterocíclicos y sus usos
MA34591B1 (fr) 2010-10-06 2013-10-02 Glaxosmithkline Llc Dérivés de benzimidazole utilisés comme inhibiteurs de pi3 kinase
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン, エルエルシー 複素環化合物およびその使用
US9096605B2 (en) * 2011-08-24 2015-08-04 Glaxosmithkline Llc Pyrazolopyrimidine derivatives as PI3 kinase inhibitors
US8906910B2 (en) 2011-12-20 2014-12-09 Glaxosmithkline Llc Imidazopyridine derivatives as PI3 kinase
US8778937B2 (en) 2011-12-20 2014-07-15 Glaxosmithkline Llc Benzimidazole boronic acid derivatives as PI3 kinase inhibitors
TWI574962B (zh) * 2012-11-14 2017-03-21 加拓科學公司 作爲pi3激酶調節劑的芳雜環化合物及其使用方法和用途
GB201321734D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents

Also Published As

Publication number Publication date
SI3233862T1 (sl) 2019-09-30
EA201791396A1 (ru) 2017-10-31
EA029789B1 (ru) 2018-05-31
CA2967551A1 (en) 2016-06-23
MA41174B1 (fr) 2019-09-30
KR20170095239A (ko) 2017-08-22
HRP20191550T1 (hr) 2019-11-29
JP2017538734A (ja) 2017-12-28
PL3233862T3 (pl) 2020-01-31
MD3233862T2 (ro) 2019-11-30
CN107108634B (zh) 2020-09-15
EP3233862A1 (en) 2017-10-25
CY1122381T1 (el) 2021-01-27
RS59301B1 (sr) 2019-10-31
BR112017012930A2 (pt) 2018-01-09
AU2015366190B2 (en) 2020-01-23
CN107108634A (zh) 2017-08-29
IL252866A0 (en) 2017-08-31
LT3233862T (lt) 2019-09-10
DK3233862T3 (da) 2019-10-07
PT3233862T (pt) 2019-10-09
MX2017008074A (es) 2018-01-09
AU2015366190A1 (en) 2017-05-25
ES2761051T3 (es) 2020-05-18
US20180002336A1 (en) 2018-01-04
ME03517B (me) 2020-04-20
WO2016097347A1 (en) 2016-06-23
IL252866B (en) 2020-09-30
MA41174A (fr) 2017-10-25
HUE045220T2 (hu) 2019-12-30
US10087187B2 (en) 2018-10-02
JP6568588B2 (ja) 2019-08-28
EP3233862B1 (en) 2019-07-03

Similar Documents

Publication Publication Date Title
IL287113A (en) smyd inhibitors
IL246785A0 (en) Benzimidazole-2-amines as midh1 inhibitors
IL251420A0 (en) Triazolopyrazinones as pde1 inhibitors
SG11201610904UA (en) Syk inhibitors
IL248895A0 (en) Phosphatidylinositol 3-kinase inhibitors
IL251932A0 (en) Benzylpropargyl ether as nitrification inhibitors
IL251778A0 (en) Novel pyrazolopyrimidine histories as nik inhibitors
SG11201609205WA (en) Heterocyclyl-butanamide derivatives
PL3418273T3 (pl) Pochodne flawaglin
HUE050450T2 (hu) Fluoralkil-fluorén-származékok
IL248773A0 (en) History of naphthyridinedione
IL252866A0 (en) History of imidazopyridazine as pi3kbeta inhibitors
IL248629B (en) Substances containing diheteroaryl conjugated to cycloalkyl and their uses
IL246718A0 (en) Hexahydrofuropyrroles as pde1 inhibitors
PL3119744T3 (pl) Pochodne 2-cyjano-3-cyklopropylo-3-hydroksy-N-arylo-tioakryloamidu
IL252868A0 (en) History of heterocyclyl-related imidazopyridazines as pi3kbeta inhibitors
GB201418154D0 (en) Inhibitors